menu
    • menu
    [{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Highlight Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BO-112","moa":"Toll-like-3 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Highlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Highlight Therapeutics \/ Highlight Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Highlight Therapeutics \/ Highlight Therapeutics"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BO-112","moa":"Toll-like-3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Highlight Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Highlight Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"BO-112","moa":"Toll-like-3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Highlight Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Highlight Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"BO-112","moa":"||Toll-like-3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Highlight Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Highlight Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"BO-112","moa":"||Toll-like-3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Highlight Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Highlight Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BO-112","moa":"||Toll-like-3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Highlight Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Highlight Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Pivotal Bioventure Partners","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BO-112","moa":"||Toll-like-3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Highlight Therapeutics \/ Pivotal Bioventure Partners","highestDevelopmentStatusID":"8","companyTruncated":"Highlight Therapeutics \/ Pivotal Bioventure Partners"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"BO-112","moa":"||Toll-like-3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Highlight Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Highlight Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BO-112","moa":"Toll-like-3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Highlight Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Highlight Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Pivotal S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Cell & Gene Therapy","year":"2016","type":"Inapplicable","leadProduct":"BO-112","moa":"Toll-like-3 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Highlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Highlight Therapeutics \/ Pivotal S.L.","highestDevelopmentStatusID":"6","companyTruncated":"Highlight Therapeutics \/ Pivotal S.L."},{"orgOrder":0,"company":"Highlight Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Collaboration","leadProduct":"BO-112","moa":"||Toll-like-3 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Highlight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Highlight Therapeutics \/ Highlight Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Highlight Therapeutics \/ Highlight Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Highlight Therapeutics

    Menu

    Highlight Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BO-112

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial to Evaluate BO-112 in Patients with Basal Cell Carcinoma (BCC)

                            Details : BO-112 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Basal Cell.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 21, 2024

                            Lead Product(s) : BO-112

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BO-112,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Highlight Therapeutics to present at the American Association for Cancer Research (AACR) Annual Meeting 2022

                            Details : BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn 'cold' tumors 'hot' and therefore visible to the immune system.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 15, 2022

                            Lead Product(s) : BO-112,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BO-112

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Clínica Universidad de Navarra

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC

                            Details : BO-112 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 03, 2022

                            Lead Product(s) : BO-112

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Clínica Universidad de Navarra

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BO-112,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Highlight Therapeutics To Present Phase 2 Data at AACR

                            Details : Presentation will cover Phase IIa open-label clinical study of intratumoral administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 14, 2021

                            Lead Product(s) : BO-112,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BO-112,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Highlight & Pivotal start Phase IIA Melanoma Trial

                            Details : Trial will examine administration of Highlight's BO-112 in combination with an anti-PD1 in unresectable or metastatic melanoma patients.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 02, 2021

                            Lead Product(s) : BO-112,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BO-112,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Pivotal Bioventure Partners

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Highlight Therapeutics & Pivotal Advance into a Phase IIa Trial to Examine Gastro-Intestinal Cancer Therapy

                            Details : First cohort of patients has been recruited in a Phase IIa study to assess Highlight’s lead program BO-112 in combination with an anti-PD1 therapy, in patients with liver metastasis from colorectal or gastric/gastro-esophageal junction cancers.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 21, 2020

                            Lead Product(s) : BO-112,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Pivotal Bioventure Partners

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BO-112

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BO-112 With Pembrolizumab in Unresectable Malignant Melanoma

                            Details : BO-112 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Melanoma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 30, 2020

                            Lead Product(s) : BO-112

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BO-112,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Highlight Therapeutics Announces Second Collaboration with MSD to Evaluate Combination of BO-112 and KeytrudaÂ...

                            Details : The collaboration will focus on the Phase II evaluation of the combination of BO-112, Highlight’s lead program, and KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients that have progressed on anti-PD-1- based therapy in refractory advanc...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            September 02, 2020

                            Lead Product(s) : BO-112,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BO-112

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis

                            Details : BO-112 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 11, 2020

                            Lead Product(s) : BO-112

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Highlight Therapeutics

                            Spain arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BO-112,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Highlight Therapeutics Announces First Patient Dosed in Phase IIa Study in Liver Metastasis

                            Details : Highlight Therapeutics dosed first patient in a Phase IIa clinical evaluation of the combination of BO-112, Highlight's lead program, and KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with select advanced stage solid tumors with liver ...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            June 26, 2020

                            Lead Product(s) : BO-112,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth